BACKGROUND: The S100A8/A9 complex is expressed in a subset of activated neutrophils and macrophages in acute inflammatory lesions associated with various diseases. OBJECTIVE: To investigate (a) whether serum S100A8/A9 levels are increased in patients with unstable angina (UA); and (b) whether S100A8/A9 expression is upregulated in coronary atherosclerotic plaques of patients with UA. DESIGN: Serum S100A8/A9 levels in 39 patients with stable angina (SA) and 53 patients with UA were measured. In addition, the presence of the S100A8/A9 complex in directional coronary atherectomy specimens was studied immunohistochemically. Cell types which stain positive for S100A8/A9 were identified by immunodouble staining with neutrophils and macrophages. RESULTS: Mean (SD) serum S100A8/A9 levels were significantly higher in patients with UA than in those with SA (3.25 (3.08) microg/ml vs 0.77 (0.31) microg/ml, p<0.05). In patients with UA, immunodouble staining clearly showed that the S100A8/A9 complex was expressed in infiltrated neutrophils and occasional macrophages. The S100A8/A9-positive area was significantly higher in UA than in SA (mean (SD) 18.3 (14.2)% vs 1.3 (2.4)%, respectively, p<0.001). CONCLUSIONS: The S100A8/A9 complex may be involved in the inflammatory process of coronary atherosclerotic plaques in patients with UA.
BACKGROUND: The S100A8/A9 complex is expressed in a subset of activated neutrophils and macrophages in acute inflammatory lesions associated with various diseases. OBJECTIVE: To investigate (a) whether serum S100A8/A9 levels are increased in patients with unstable angina (UA); and (b) whether S100A8/A9 expression is upregulated in coronary atherosclerotic plaques of patients with UA. DESIGN: Serum S100A8/A9 levels in 39 patients with stable angina (SA) and 53 patients with UA were measured. In addition, the presence of the S100A8/A9 complex in directional coronary atherectomy specimens was studied immunohistochemically. Cell types which stain positive for S100A8/A9 were identified by immunodouble staining with neutrophils and macrophages. RESULTS: Mean (SD) serum S100A8/A9 levels were significantly higher in patients with UA than in those with SA (3.25 (3.08) microg/ml vs 0.77 (0.31) microg/ml, p<0.05). In patients with UA, immunodouble staining clearly showed that the S100A8/A9 complex was expressed in infiltrated neutrophils and occasional macrophages. The S100A8/A9-positive area was significantly higher in UA than in SA (mean (SD) 18.3 (14.2)% vs 1.3 (2.4)%, respectively, p<0.001). CONCLUSIONS: The S100A8/A9 complex may be involved in the inflammatory process of coronary atherosclerotic plaques in patients with UA.
Authors: David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A Katus; Thomas G Parker; Patrick Most Journal: J Cardiovasc Transl Res Date: 2010-07-20 Impact factor: 4.132
Authors: Carolin Kraus; David Rohde; Christian Weidenhammer; Gang Qiu; Sven T Pleger; Mirko Voelkers; Melanie Boerries; Andrew Remppis; Hugo A Katus; Patrick Most Journal: J Mol Cell Cardiol Date: 2009-06-16 Impact factor: 5.000
Authors: Jie Zhang; Pilar Alcaide; Li Liu; Jiusong Sun; Aina He; Francis W Luscinskas; Guo-Ping Shi Journal: PLoS One Date: 2011-01-14 Impact factor: 3.240
Authors: Matthew P Welberry Smith; Steven L Wood; Alexandre Zougman; Jenny T C Ho; Jianhe Peng; David Jackson; David A Cairns; Andrew J P Lewington; Peter J Selby; Rosamonde E Banks Journal: Proteomics Date: 2011-05-05 Impact factor: 3.984
Authors: Sarah R Langley; Karin Willeit; Athanasios Didangelos; Ljubica Perisic Matic; Philipp Skroblin; Javier Barallobre-Barreiro; Mariette Lengquist; Gregor Rungger; Alexander Kapustin; Ludmilla Kedenko; Chris Molenaar; Ruifang Lu; Temo Barwari; Gonca Suna; Xiaoke Yin; Bernhard Iglseder; Bernhard Paulweber; Peter Willeit; Joseph Shalhoub; Gerard Pasterkamp; Alun H Davies; Claudia Monaco; Ulf Hedin; Catherine M Shanahan; Johann Willeit; Stefan Kiechl; Manuel Mayr Journal: J Clin Invest Date: 2017-03-20 Impact factor: 14.808